

B2B-Licensing Product List

Q1 2024



EU-GMP Dossiers Available

Active substance	Dosage form	Strength	Form	Indication
8-Methoxypsoralen (Oxsoralen®)	Ampoules ^{IVa/b}	0.02 mg/ml (5 ml)		Cutaneous T-Cell Lymphoma
Acetylsalicylic Acid	Gastro-resistant tablets	75 mg, 100 mg, 160 mg		Antithrombotic
	Tablets	75 mg, 100 mg		
Buprenorphine	Sublingual tablets	0.2 mg, 0.4 mg		Severe Pain
		1 mg, 2 mg		Opioid Use Disorder
		4 mg, 6 mg, 8 mg, 12 mg, 16 mg		
Buprenorphine + Naloxone	Sublingual tablets ^{IVa/b}	2 mg+0.5 mg, 4 mg+1 mg, 8 mg+2 mg	NEW	Opioid Use Disorder
Esketamine	Solution for injection or infusion ^{IVa/b}	5 mg/ml (2 ml, 5 ml, 10 ml), 25 mg/ml (2 ml, 5 ml, 10 ml)		Severe Pain, Narcotic
		5 mg/ml (5 ml, 10 ml, 20 ml), 25 mg/ml (5 ml, 10 ml, 20 ml)		
Eslicarbazepine	Tablets	200 mg, 400 mg, 600 mg, 800 mg		Epilepsy
Eszopiclone	Film-coated tablets ^{IVa}	1 mg, 2 mg, 3 mg		Insomnia
Ethosuximide	Syrup ^{IVa/b}	50 mg/ml (250 ml)		Epilepsy
Fe ²⁺ + Ascorbic Acid + Folic Acid (Ferretab® comp plus)	Capsules	66.7 mg+100 mg+0.8 mg		Anaemia during Pregnancy
Fluoxetine	Film-coated tablets	20 mg ^{IVa/b} 40 mg		Depression
Folic Acid	Tablets	1 mg, 5 mg		Folic Acid Deficiency
Hydromorphone	Solution for injection ^{IVa/b}	2 mg/ml (1 ml), 10 mg/ml (1 ml, 10 ml) 20 mg/ml (1 ml), 50 mg/ml (1 ml)		Severe Pain
Ketamine	Solution for injection or infusion ^{IVa/b}	10 mg/ml (2 ml, 5 ml, 10 ml), 50 mg/ml (2 ml, 5 ml, 10 ml)		Severe Pain, Narcotic
		10 mg/ml (5 ml, 10 ml, 20 ml), 50 mg/ml (5 ml, 10 ml, 20 ml)		
Lacosamide	Film-coated tablets ^{IVa/b}	50 mg, 100 mg, 150 mg, 200 mg		Epilepsy
	Oral solution	10 mg/ml (200 ml, 500 ml)		
	Solution for infusion ^{IVa/b}	10 mg/ml (10 ml, 20 ml)		
		10 mg/ml (20 ml)		
Levetiracetam	Oral solution	100 mg/ml (150 ml, 300 ml)		Epilepsy
	Conc. for solution for infusion ^{IVa/b}	100 mg/ml (5 ml)		
Levomethadone	Tablets ^{IVa/b}	2.5 mg, 5 mg, 10 mg, 20 mg, 30 mg	/ /	Opioid Use Disorder
	Conc. for oral solution	5 mg/ml (100 ml, 150 ml, 300 ml, 500 ml, 1000 ml)		

IVa/b: Zone IVa/b stability data available

EU-GMP Dossiers Available

Active substance	Dosage form	Strength	Form	Indication
Metamizole	Solution for injection ^{IVa/b}	500 mg/ml (2 ml, 5 ml)		Mild to Moderate Pain
Methadone	Tablets ^{IVa/b}	5 mg, 10 mg, 20 mg, 40 mg, 60 mg	/ /	Opioid Use Disorder
	Conc. for oral solution	10 mg/ml (100 ml, 150 ml, 300 ml, 500 ml, 1000 ml)		
Metoclopramide	Oral solution ^{IVa/b}	1 mg/ml (150 ml)		Nausea, Emesis
	Solution for injection or infusion ^{IVa/b}	5 mg/ml (2 ml, 10 ml)		
Morphine	Solution for injection ^{IVa/b}	10 mg/ml (1 ml)		Severe Pain
		10 mg/ml (10 ml), 20 mg/ml (10 ml)		
	Film-coated tablets ^{IVa/b}	5 mg, 10 mg, 20 mg	/	
Oxycodone	Prolonged-release tablets	5 mg, 10 mg, 15 mg, 20 mg, 30 mg, 40 mg, 60 mg, 80 mg		Severe Pain
	Oral solution ^{IVa/b}	1 mg/ml (100 ml, 250 ml, 300 ml)		
		10 mg/ml (30 ml, 100 ml, 120 ml)		
Oxycodone + Naloxone*	Solution for injection or infusion ^{IVa/b}	10 mg/ml (1 ml, 2 ml)		Severe Pain
	Prolonged-release tablets	5 mg+2.5 mg, 10 mg+5 mg, 20 mg+10 mg, 30 mg+15 mg, 40 mg+20 mg		
	Film-coated tablets ^{IVa/b}	2 mg, 4 mg, 6 mg, 8 mg, 10 mg, 12 mg		Epilepsy
Potassium Iodide	Tablets	65 mg		Radiation Prophylaxis
	Prolonged-release tablets ^{IVa/b}	25 mg, 50 mg, 100 mg, 150 mg, 200 mg, 250 mg	/	
Tapentadol	Film-coated tablets ^{IVa/b}	25 mg, 50 mg, 75 mg, 100 mg		Severe Pain
	Oral solution ^{IVa/b}	20 mg/ml (100 ml, 200 ml)		
Tizanidine	Tablets ^{IVa/b}	2 mg, 4 mg, 6 mg		Muscle Spasms
Trazodone	Oral solution ^{IVa/b}	10 mg/ml (120 ml)		Depression
Valproic Acid/ Sodium Valproate	Oral solution ^{IVa}	300 mg/ml (100 ml)		Epilepsy
Vitamin B ₁ (B ₁ =Benfotiamine)	Film-coated tablets	50 mg, 150 mg		Vitamin B ₁ Deficiency
		300 mg		
Vitamin B ₁₂ (B ₁₂ =Hydroxocobalamin)	Solution for injection	1 mg/ml (1 ml)		Vitamin B ₁₂ Deficiency
Vitamin B ₁ + B ₆ (B ₁ =Benfotiamine)	Film-coated tablets	100 mg+100 mg		Vitamin B Deficiency
Vitamin D ₃	Oral solution ^{IVa/b}	14 400 IU/ml (12.5 ml, 30 ml)		Vitamin D ₃ Deficiency
		28 800 IU/ml (12.5 ml, 30 ml, 50 ml)		

IVa/b: Zone IVa/b stability data available /*No availability in the EU

Dossier Update Pending

Active substance	Dosage form	Strength	Form	Indication
Fe ²⁺ + Ascorbic Acid (Ferretab®)	Capsules	100 mg+20 mg	□	Anaemia
Fe ²⁺ + Folic Acid (Ferretab® comp)	Capsules	50 mg+0.5 mg	□	Anaemia during Pregnancy
Tramadol	Solution for injection	50 mg/ml (2 ml)	○—○	Moderate to Severe Pain
	Oral drops	100 mg/ml (10 ml, 30 ml, 50 ml)	○	
Valproic Acid/ Sodium Valproate	Gastro-resistant soft capsules ^{IVa}	150 mg, 300 mg, 500 mg	□	Epilepsy
	Syrup ^{IVa}	50 mg/ml (100 ml)	○	
	Solution for injection ^{IVa/b}	100 mg/ml (5 ml)	○—○	
Vitamin B ₁ + B ₆ + B ₁₂ (Neuromultivit®)	Film-coated tablets	100 mg+200 mg+0.2 mg	□	Vitamin B Deficiency, Neuropathic Pain
	Solution for injection	50 mg+50 mg+0.5 mg/ml (2 ml)	○—○	

EU-GMP Dossiers Under Development

Active substance	Dosage form	Strength	Dossier availability	Indication
Brivaracetam	Film-coated tablets	10 mg, 25 mg, 50 mg, 75 mg, 100 mg	Q1 2024	Epilepsy
Buprenorphine + Naloxone	Sublingual tablets	12 mg+3 mg,	Q4 2024	Opioid Use Disorder
Candesartan + Chlortalidone	Tablets	8 mg+12.5 mg, 16 mg+12.5 mg, 32 mg+12.5 mg, 32 mg+25 mg	2025	High Blood Pressure
Hydromorphone	Film-coated tablets	1.3 mg, 2.6 mg	Q1 2024	Severe Pain
Hydromorphone	Prolonged-release capsules	2 mg, 4 mg, 8 mg, 16 mg, 24 mg	2026	Severe Pain
Trazodone	Prolonged-release tablets	75 mg, 150 mg	2025	Depression
Vitamin B ₁ + B ₆ + B ₁₂ (B ₁ =Benfotiamine)	Film-coated tablets	40 mg+90 mg+0,25 mg	Q4 2023	Vitamin B Deficiency

Zone IVa/b stability data planned for all products under development

Products protected by valid patents will not be offered for sale or supplied in countries where the respective patents are in force. Please be advised that information on this list is subject to change. For markets with special requirements please check availability with our licensing managers.

Contact Details

G.L. Pharma GmbH
Schlossplatz 1
8502 Lannach, Austria
E: licensing@gl-pharma.at
T: +43 3136 82 577

